• CDT Equity has begun preclinical human-skin studies with QIMA Life Sciences to evaluate its proprietary tapinarof combinations for vitiligo.
• Testing will use tissue from healthy donors and patients to generate evidence of activity ahead of potential clinical development.
• Positive results would underpin a licensing package; the strategy is to license the combinations to a partner for commercialization.
• The global vitiligo drug market was estimated at approximately US$2.6 billion in 2025, with projections reaching US$6.6 billion by 2030.
• Vitiligo affects approximately 0.5%-2% of the global population; current treatments can be intolerable, particularly for pediatric patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110700PRIMZONEFULLFEED9875343) on November 11, 2026, and is solely responsible for the information contained therein.